01 May 2006
APOBEC deaminases as cellular antiviral factors: A novel natural host defense mechanism
Raffaella Franca, Silvio Spadari, Giovanni MagaMed Sci Monit 2006; 12(5): RA92-98 :: ID: 450299
Abstract
The APOBEC (acronym for apolipoprotein B editing catalytic polypeptide)family of cytidine deaminases are widely distributed in the biological world and play a central rolein diverse enzymatic pathways. Members of this family (APOBEC3G and APOBEC3F) have been recently shownto be able to restrict HIV-1 replication in physiologically relevant target cells (macrophages, lymphocytes),presumably by triggering extensive deamination of the viral RNA/DNA replication intermediates. This naturalantiretroviral host defense mechanism is counteracted by the HIV-1 protein Vif, which is able to targetAPOBECs to degrade. The so-called "Vif/APOBEC3G paradigm" has been confirmed by a growing literature.However, evidence arising from recent studies has expanded this view, showing that the replication ofother viruses is also restricted by APOBEC family members and suggesting antiviral mechanism(s) of actionunrelated to the catalytic activity of these proteins. Furthermore, evolutionary investigations on primateshave shown that APOBEC3 gene expansion might be related to an ancient adaptive selection to prevent endogenousgenetic instability, indicating an additional ancient protective role of APOBECs. This article is aimedat broadening the current knowledge about the antiviral activity of the APOBEC members and to highlightthe notion that their role(s) might be more general than previously anticipated.
Keywords: Amino Acid Sequence, Anti-HIV Agents - metabolism, Cytidine Deaminase - metabolism, Gene Products, vif - metabolism, HIV Infections - virology, HIV-1 - physiology, Molecular Sequence Data, Nucleoside Deaminases - metabolism, Repressor Proteins - metabolism, Sequence Homology, Amino Acid, Virus Replication, vif Gene Products, Human Immunodeficiency Virus
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
08 Feb 2024 : Database Analysis
Comparative Accuracy of Intraoral and Extraoral Digital Workflows for Short Span Implant Supported Fixed Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943706
08 Feb 2024 : Clinical Research
Serum Selenium Concentration as a Potential Diagnostic Marker for Early-Stage Colorectal Cancer: A Comparat...Med Sci Monit In Press; DOI: 10.12659/MSM.942882
09 Feb 2024 : Clinical Research
Factors Influencing the Occurrence of Intraoperative Hypothermia in Patients Undergoing General Anesthesia ...Med Sci Monit In Press; DOI: 10.12659/MSM.943463
13 Feb 2024 : Clinical Research
A Retrospective Study to Compare the Glasgow Coma Score, Pediatric Trauma Score, and Injury Severity Score ...Med Sci Monit In Press; DOI: 10.12659/MSM.943501
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952